What is HC Wainwright’s Estimate for Prothena Q4 Earnings?

Prothena Co. plc (NASDAQ:PRTA) – Equities research analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of Prothena in a report released on Friday, February 21st. HC Wainwright analyst A. Fein anticipates that the biotechnology company will earn ($0.58) per share for the quarter. HC Wainwright has a “Buy” rating and a $48.00 price target on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.12 million for the quarter, compared to analyst estimates of $7.53 million.

PRTA has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research note on Friday. StockNews.com lowered Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. Chardan Capital reissued a “buy” rating and set a $40.00 price objective on shares of Prothena in a report on Friday. Oppenheimer boosted their price objective on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a report on Friday, February 7th. Finally, Royal Bank of Canada decreased their price objective on Prothena from $24.00 to $20.00 and set a “sector perform” rating for the company in a report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Prothena currently has a consensus rating of “Moderate Buy” and an average price target of $45.83.

Prothena Stock Performance

PRTA stock opened at $15.56 on Monday. The stock’s 50 day simple moving average is $14.33 and its 200 day simple moving average is $16.76. Prothena has a fifty-two week low of $11.70 and a fifty-two week high of $31.03. The company has a market cap of $837.27 million, a P/E ratio of -6.77 and a beta of 0.08.

Hedge Funds Weigh In On Prothena

Institutional investors have recently modified their holdings of the business. Barclays PLC grew its holdings in shares of Prothena by 110.2% in the third quarter. Barclays PLC now owns 95,222 shares of the biotechnology company’s stock valued at $1,592,000 after acquiring an additional 49,916 shares in the last quarter. SG Americas Securities LLC grew its holdings in Prothena by 167.0% during the fourth quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company’s stock valued at $521,000 after purchasing an additional 23,525 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Prothena by 1,122.9% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock valued at $8,812,000 after purchasing an additional 483,673 shares during the period. Duncan Williams Asset Management LLC grew its holdings in Prothena by 41.9% during the fourth quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company’s stock valued at $958,000 after purchasing an additional 20,450 shares during the period. Finally, Focused Wealth Management Inc bought a new position in Prothena during the fourth quarter valued at $445,000. 97.08% of the stock is owned by institutional investors.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.